文献速递血栓与止血

因子XIII与止血剂联合治疗血友病A可增加纤维蛋白α链交联

Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
PubMed 文献 · J Thromb Haemost · 2017-11-20

在血友病A血浆和全血中,FXIII与止血剂(FVIII、rFVIIa、FEIBA或rpFVIII)联合治疗可加速FXIIIa形成、增加纤维蛋白α链交联种类和数量、加速α2-抗纤溶酶交联并增加血凝块重量,为FXIII联合治疗提供生化依据。

要点

  • 与FVIII单药相比,FVIII+FXIII联合治疗加速FXIIIa形成但不增加凝血酶生成。
  • 与缓冲液或FXIII单药相比,FVIII及FVIII+FXIII增加交联纤维蛋白生成和数量。
  • 存在FVIII抑制物时,FXIII联合治疗较止血剂单药增加全血血凝块重量。

核心结论

  • 在血友病A血浆和全血中,FXIII与止血剂联合治疗加速FXIIIa形成、增加纤维蛋白α链交联种类和数量、加速α2-抗纤溶酶交联并增加血凝块重量。
  • FXIII与止血治疗联合可能通过增加纤维蛋白和α2-抗纤溶酶交联来增强止血。

研究设计与样本

  • 体外研究:使用FVIII缺乏血浆和全血,在有无止血剂(FVIII、rFVIIa、FEIBA或rpFVIII)和/或FXIII条件下进行凝血。
  • 通过蛋白质印迹、校准自动血栓造影、血栓弹力图和血凝块收缩试验测量FXIII活化、凝血酶生成、纤维蛋白和α2-抗纤溶酶交联、血凝块形成和血凝块重量。

主要发现

  • 与FVIII治疗的血友病血浆相比,FVIII+FXIII联合治疗加速FXIIIa形成而不增加凝血酶生成。
  • 与缓冲液处理或FXIII处理的血友病血浆相比,FVIII治疗和FVIII+FXIII联合治疗增加交联纤维蛋白的生成和数量,包括富含α链的高分子量种类和交联的α2-抗纤溶酶。
  • 存在FVIII抑制物时,与止血治疗(rFVIIa、FEIBA或rpFVIII)单药相比,FXIII联合治疗增加全血血凝块重量。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Factor XIII (FXIII)-mediated fibrin crosslinking is delayed in hemophilia. We determined effects of FXIII cotreatment with hemostatic agents on clot parameters. FXIII cotreatment accelerated FXIII activation and crosslinking of fibrin and α2 -antiplasmin. These data provide biochemical rationale for FXIII cotreatment in hemophilia. SUMMARY: Background Hemophilia A results from the absence, deficiency or inhibition of factor VIII. Bleeding is treated with hemostatic agents (FVIII, recombinant activated FVII [rFVIIa], anti-inhibitor coagulation complex [FEIBA], or recombinant porcine FVIII [rpFVIII]). Despite treatment, some patients have prolonged bleeding. FXIII-A2 B2 (FXIII) is a protransglutaminase. During clot contraction, thrombin-activated FXIII (FXIIIa) crosslinks fibrin and α2 -antiplasmin, which promotes red blood cell retention and increases clot stability and weight. We hypothesized that FXIII cotreatment in hemophilia would accelerate FXIII activation, leading to increased fibrin crosslinking. Methods FVIII-deficient plasma and whole blood were clotted with or without hemostatic agents (FVIII, rFVIIa, FEIBA, or recombinant B-domain-deleted porcine FVIII [rpFVIII]) and/or FXIII. The effects on FXIII activation, thrombin generation, fibrin and α2 -antiplasmin crosslinking, clot formation and clot weight were measured by western blotting, calibrated automated thrombography, thromboelastography, and clot contraction assays. Results As compared with FVIII-treated hemophilic plasma, FVIII + FXIII cotreatment accelerated FXIIIa formation without increasing thrombin generation. As compared with buffer-treated or FXIII-treated hemophilic plasma, FVIII treatment and FVIII + FXIII cotreatment increased the generation and amount of crosslinked fibrin, including α-chain-rich high molecular weight species and crosslinked α2 -antiplasmin. In the presence of FVIII inhibitors, as compared with hemostatic treatments (rFVIIa, FEIBA, or rpFVIII) alone, FXIII cotreatment increased whole blood clot weight. Conclusion In hemophilia A plasma and whole blood, FXIII cotreatment with hemostatic agents accelerated FXIIIa formation, increased the generation and amount of fibrin α-chain crosslinked species, accelerated α2 -antiplasmin crosslinking, and increased clot weight. FXIII cotreatment with hemostatic therapy may augment hemostasis through increased crosslinking of fibrin and α2 -antiplasmin.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Beckman JD, Holle LA, Wolberg AS, et al. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking. J Thromb Haemost. 2017. PMID: 29080382. doi:10.1111/jth.13887

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。